TCL Archive Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment. July 30, 2004
TCL Archive NCI Ends Brash Foray Into the News Business—Emails Tell the Story of the NCI Cancer Bulletin February 1, 2013
TCL Archive Army Hopes To Fund “Middle-Risk, high Payoff” Research With Breast Cancer money. Travis Says February 19, 1993
